A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02259582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT02259582
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Pemetrexed Drug
- demcizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2015
- Primary completion
- Apr 6, 2017
- Completion
- Apr 6, 2017
- Last update posted
- Sep 8, 2020
2015 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| University of California, San Francisco | San Francisco | California | . 94143-1705 | — |
| Smilow Cancer Hospital at Yale-New Haven | New Haven | Connecticut | 06510-3221 | — |
| Ocala Oncology Center | Ocala | Florida | 34471 | — |
| Edward H. Kaplan MD & Associates | Skokie | Illinois | 60076 | — |
| Anne Arundel Medical Center | Annapolis | Maryland | 21401 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 4820I | — |
| Broome Oncology, LLC | Binghamton | New York | 13905 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Hematology Oncology Associates of Rockland | Nyack | New York | 10960 | — |
| Gaston Hematology & Oncology | Gastonia | North Carolina | 28054 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| University of Texas Medical Branch at Galveston | Galveston | Texas | 77555 | — |
| Texas Oncology-Sherman | Sherman | Texas | 75090-0504 | — |
| Compass Oncology | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02259582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2020 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02259582 live on ClinicalTrials.gov.